''Dxcover...today announced that its breakthrough liquid biopsy medical device has successfully achieved CE marking under the European In Vitro Diagnostic Regulation (IVDR) (EU) 2017/746.''
"Dxcover...today announced the availability of its UKCA1-marked, blood-based brain cancer early detection test in the UK...The new validated test has demonstrated a 99.3% negative predictive value2 (NPV), enabling GPs to provide earlier reassurance to symptomatic patients, inform referral into imaging, and reach an earlier diagnosis."